Key Highlights

  • Loss per share was USD 0.23 against an estimate of a USD 0.21 loss.
  • Research and development expense was USD 18.14 million, against USD 14.35 million.
  • Cash and short-term investments were USD 169.7 million at September 30.
  • The company's cash is sufficient into the second half of 2028.

Whitehawk Therapeutics (NASDAQ:WHWK) reported a third quarter 2026 loss per share of USD 0.23, against an estimate of a USD 0.21 loss and a USD 0.26 loss in the third quarter of 2025. The company reported the figures in its quarterly filing for the period ended September 30, 2026.

The loss from operations was USD 22.94 million, compared with USD 19.55 million a year earlier. The filing shows no Revenue for the quarter, and total operating expenses of USD 22.94 million, against USD 19.55 million.

Operating Expenses and Other Income

Research and development expense was USD 18.14 million, compared with USD 14.35 million, while selling, general and administrative expense was USD 4.81 million, compared with USD 5.20 million. Other income, net, was USD 1.73 million, compared with USD 1.80 million.

For the nine months ended September 30, 2026, Research and Development expense was USD 48.26 million, against USD 71.94 million, and selling, general and administrative expense was USD 16.31 million, against USD 23.96 million. Total operating expenses were USD 64.57 million, against USD 96.66 million.

Nine-Month Comparison

The nine-month loss from operations was USD 64.57 million, compared with USD 89.51 million. Other income, net, for the nine months was USD 4.53 million, compared with USD 92.17 million in the prior-year period, which included a gain on sale of business. Prior-year nine-month revenue was USD 7.15 million from product sales, net, with none in 2026.

Basic and diluted loss per share for the nine months was USD 0.73, compared with Earnings Per Share of USD 0.04 in the prior-year period.

Restructuring, Licensing and Liquidity

The filing describes a restructuring plan announced on August 21, 2024 to reduce the company's workforce by approximately 32% in response to its decision to halt the registration-intended PRECISION1 trial of nab-sirolimus in patients with solid tumors harboring TSC1 or TSC2 inactivating alterations. Restructuring payments commenced in September 2024 and were completed in March 2026.

The filing also notes that stockholders approved a 2021 employee stock purchase plan that permits participants to contribute up to 15% of eligible compensation during defined periods.

In December 2024, the company entered into an intellectual property license agreement with WuXi Biologics related to antibody drug conjugate therapies. As of September 30, 2026, it had USD 169.7 million of cash, cash equivalents and short-term investments, including cash and cash equivalents of USD 68.97 million and short-term investments of USD 100.70 million. The company believes this funds planned operations into the second half of 2028.

Whitehawk Therapeutics Q3 2026 Earnings: Key Takeaways

Whitehawk Therapeutics reported a third quarter 2026 loss per share of USD 0.23 and research and development expense of USD 18.14 million. Cash, cash equivalents and short-term investments were USD 169.7 million, which the company believes funds operations into the second half of 2028.